Creative Biogene Has Developed GMP Lentivirus Production Service to Accelerate Cell Therapy and Gene Therapy

Creative Biogene announced the release of its GMP lentivirus production service to accelerate cell therapy and gene therapy-related research.

USA – December 1, 2022 /MarketersMEDIA/ —

Creative Biogene is dedicated to helping scientists break new ground with innovative technologies. The extensive portfolio of reagents, instruments, and services supports advancements in the life sciences, including frontline diagnostics and clinical applications. With a professional scientific team, Creative Biogene is capable to support a wide range of applications including CAR-T therapy, immune profiling, genetic screening, cell and gene therapy, infectious disease research, vaccine development, drug discovery, antibiotic-resistance screening, and cancer research. Recently, Creative Biogene announced the release of its GMP lentivirus production service to accelerate cell therapy and gene therapy-related research.

Creative Biogene has over 10 years of experience in viral vector production and has a track record of more than 100 virus and cell bank production projects, manufactured and tested according to GMP guidelines. The one-stop GMP manufacturing facility can support a wide range of manufacturing needs, from small-scale prototyping early in development to large-scale manufacturing up to 2,000 L.

Creative Biogene assists clients in the GMP manufacture of a variety of viral vectors, including lentivirus, adenovirus, and adeno-associated virus (AAV), with a focus on streamlining the platform process and accelerating the transition to the clinic. With years of experience in the production, purification and characterization of viral products, Creative Biogene can provide the most affordable and high-quality GMP-grade viral services.

GMP production of clinical-grade lentiviruses for gene therapy requires integrated method technologies to produce, purify, and characterize lentiviruses in a well-established GMP quality system. As a leader in lentiviral production, Creative Biogene combines leading lentiviral production technology with developed systematic GMP program controls to ensure clinical product quality, safety and consistency for gene therapy clinical trials. Creative Biogene has developed a proprietary, highly efficient system for ultra-high titer lentiviral production, including production at a clinical scale.

Creative Biogene has designed three separate state-of-the-art GMP facilities dedicated to microbiology, cell culture and virus production, and provides QA and QC groups to oversee documentation required from equipment validation to approval of GMP products (SOPs, batch records, validation reports, etc. ) of the entire production process.

“Our mission is to develop high-quality innovative tools and services to accelerate discovery.” said Marcia Brady, the marketing director of Creative Biogene, she also added, “Our custom virus services deliver virus counts with consistently high titers and high volumes to assist in all areas of viral vector design and construction.”

About Creative Biogene

Creative Biogene is a top-of-its-kind company that holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools, and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.

Contact Info:
Name: Marcia Brady
Email: Send Email
Organization: Creative Biogene
Address: Shirley, NY 11967, USA
Phone: 6313868241
Website: https://www.creative-biogene.com/

Release ID: 89085803

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.